Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
sitagliptin Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)
Sobos Insight: Think of muscle as your metabolic engine
A substantial volume of data indicates that an elevated HR is independently associated with increased cardiovascular morbidity and mortality in the general population, in subjects with cardiovascular diseases, and those with diabetes [13, 14, 38, 39]
Broader reviews on dietary fiber and health also support the role of fermentable fibers in metabolic outcomes here
